Clinical Report: Predictive Model for Early Progression of LV Dysfunction in HCM
Overview
This study developed and validated a predictive model for early left ventricular systolic dysfunction progression (ELVSDP) in patients with hypertrophic cardiomyopathy (HCM). Key independent predictors include age, smoking history, BNP levels, and left ventricular outflow tract obstruction.
Background
Hypertrophic cardiomyopathy (HCM) is a prevalent genetic disorder that can lead to severe complications such as heart failure and sudden cardiac death. Early identification of patients at risk for left ventricular systolic dysfunction progression is crucial for timely intervention and management. Current risk assessment tools are inadequate for short-term predictions, necessitating the development of more effective models.
Data Highlights
Predictor
Hazard Ratio (HR)
Age
1.17
Smoking History
2.79
BNP Level
1.002
Left Ventricular Outflow Tract Obstruction
2.24
Key Findings
The model demonstrated strong predictive performance with C-indices of 0.94 and 0.93 in training and validation sets, respectively.
Time-dependent AUC exceeded 0.88 at 6, 12, and 18 months.
Calibration curves indicated good agreement between predicted and observed outcomes.
High-risk patients had a significantly higher incidence of ELVSDP compared to low-risk patients (P < 0.0001).
Bootstrap validation confirmed the stability of the predictive model.
Clinical Implications
The nomogram developed in this study provides a quantitative tool for early risk stratification of ELVSDP in HCM patients. Clinicians can utilize this model to identify high-risk patients and implement timely interventions to improve patient outcomes.
Conclusion
This predictive model represents a significant advancement in the management of HCM, enabling healthcare providers to better anticipate and address the risk of early left ventricular systolic dysfunction progression.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
